Thomas G Lane

US Patent:

8258266, Sep 4, 2012

Filed:

May 27, 2009

Appl. No.:

12/472877

Inventors:

Shrikant Deshpande - Fremont CA, US
Haichun Huang - Fremont CA, US
Mohan Srinivasan - Cupertino CA, US
Josephine M. Cardarelli - San Carlos CA, US
Changyu Wang - Fremont CA, US
David B. Passmore - San Carlos CA, US
Vangipuram Rangan - Pleasant Hill CA, US
Thomas E. Lane - Irvine CA, US
Hans S. Keirstead - Irvine CA, US
Michael T. Liu - Irvine CA, US

Assignee:

Medarex, Inc. - Princeton NJ

International Classification:

C07K 16/00
C12P 21/08
A61K 39/395
A61K 39/40
C12N 5/02
C12N 5/16
C07K 1/00

US Classification:

5303871, 5303873, 5303879, 5303881, 53038815, 5303882, 53038823, 5303911, 4241301, 4241321, 4241341, 4241361, 4241391, 4241411, 4241421, 4241581, 4241781, 435325, 435326, 435328, 435331, 435335

Abstract:

The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.

US Patent:

8263153, Sep 11, 2012

Filed:

Apr 19, 2005

Appl. No.:

11/547986

Inventors:

Nynne M. Forchhammer - Hedehusene, DK
Beth Fryksdale - San Jose CA, US
Keith Hayes - Florence KY, US
Csilla Kollar - Midland MI, US
Thomas H. Lane - Midland MI, US
Anthony Revis - Freeland MI, US

Assignee:

Dow Corning Corporation - Midland MI

International Classification:

A23L 2/72

US Classification:

426422, 426 11, 4263303, 426423, 426424

Abstract:

The present invention provides a method for preventing or reducing haze development in a beverage. Silane-treated silica filter media are synthesized. By contacting the beverage with the silane-treated silica filter, one or more haze-forming components bind to the silane-treated silica filter media and are removed by filtration. In addition, particulates in the beverage are removed by filtration. Beverages that tend to develop haze on standing and/or chilling such as alcoholic, fruit, and vegetable beverages, are suitable for the present invention. This haze in a beverage is mainly caused by polyphenols and proteins. The present invention provides a method that can reduce the levels of both polyphenols and proteins. The silica filter media useful for the present method include rice hull ash, oat hull ash, or diatomaceous earth.

US Patent:

8271939, Sep 18, 2012

Filed:

Nov 14, 2008

Appl. No.:

12/271167

Inventors:

Ramanarayanan Krishnaiyer - Bangalore, IN
Thomas Lane - San Francisco CA, US
Sameer Bhatt - Uttar Pradesh, IN
Gaurav Priyadarshi - Jharkhand, IN
Sreenivas Ramaswarmy - Karnataka, IN
Sunil Bannur - Karnataka, IN
Mayank Kumar - Bangalore, IN

Assignee:

Adobe Systems Incorporated - San Jose CA

International Classification:

G06F 17/30

US Classification:

717106, 707795, 707804, 717110

Abstract:

An application development tool can support sampling of data from one or more providers of data that will be queried by the application under development at runtime. The sampling results can be used to provide hints or suggestions at development time so that a developer defining code segments that make reference to data resulting from such queries can produce code segments having the proper context to reference the data of interest. The sampling results can comprise a plurality of parameters and the application development tool can provide a user interface whereby a user can indicate custom type declarations for the returned parameters and/or identify a subset of the parameters returned by a query as being of interest. The custom type declarations and/or identified subset can be used to facilitate more meaningful hinting or suggestion by the application development tool.

US Patent:

20050191293, Sep 1, 2005

Filed:

Dec 10, 2004

Appl. No.:

11/009731

Inventors:

Shrikant Deshpande - Freemont CA, US
Haichun Huang - Fremont CA, US
Mohan Srinivasan - Cupertino CA, US
Josephine Cardarelli - San Carlos CA, US
Changyu Wang - Fremont CA, US
David Passmore - Mountain View CA, US
Vangipuram Rangan - Pleasant Hill CA, US
Thomas Lane - Irvine CA, US
Hans Keirstead - Irvine CA, US
Michael Liu - Irvine CA, US

International Classification:

A61K039/395
C07K016/28

US Classification:

424143100, 530388220

Abstract:

The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.

US Patent:

20060083776, Apr 20, 2006

Filed:

Oct 11, 2005

Appl. No.:

11/248017

Inventors:

Richard Bott - Burlingame CA, US
Kurt Brandstadt - Midland MI, US
Csilla Kollar - Midland MI, US
Thomas Lane - Midland MI, US
Donald Liles - Midland MI, US
Mae Saldjeno - Daly City CA, US
Xavier Thomas - Foix, FR
Kevin Murphy - Midland MI, US
Gerald Schalau - Freeland MI, US

International Classification:

A61L 15/00

US Classification:

424445000

Abstract:

A multi-layer dressing and controlled-release composition for topical application to a substrate include an emulsion and an active agent incorporated into the emulsion. The active agent includes a protein. A method of delivering the active agent to the substrate provides the emulsion and incorporates the active agent into the emulsion for delivery of the active agent to the substrate. Multi-layer dressings and methods particularly suited for management of wound exudate and effective debridement of wound eschar.

US Patent:

20070218115, Sep 20, 2007

Filed:

Oct 27, 2004

Appl. No.:

10/576356

Inventors:

Richard Bott - Burlingame CA, US
Kurt Brandstadt - Midland MI, US
Csilla Kollar - Midland MI, US
Thomas Lane - Midland MI, US
Donald Liles - Midland MI, US
Mae Saldjeno - Dale City CA, US
Xavier Thomas - Foix, FR

International Classification:

A61K 9/70

US Classification:

424445000

Abstract:

A multi-layer dressing and controlled-release composition for topical application to a substrate include an emulsion and an active agent incorporated into the emulsion. The active agent includes a protein. A method of delivering the active agent to the substrate provides the emulsion and incorporates the active agent into the emulsion for delivery of the active agent to the substrate.

US Patent:

20120230998, Sep 13, 2012

Filed:

May 23, 2012

Appl. No.:

13/478786

Inventors:

Shrikant DESHPANDE - Fremont CA, US
Haichun HUANG - Fremont CA, US
Mohan SRINIVASAN - Cupertino CA, US
Josephine M. CARDARELLI - San Carlos CA, US
Changyu WANG - Fremont CA, US
David PASSMORE - Mountain View CA, US
Vangipuram RANGAN - Pleasant Hill CA, US
Thomas E. LANE - Irvine CA, US
Hans S. KEIRSTEAD - Irvine CA, US
Michael T. LIU - Irvine CA, US

Assignee:

MEDAREX, INC. - Princeton NJ

International Classification:

A61K 39/395
A61P 25/00
A61P 19/02
A61P 29/00
A61P 1/00
A61P 9/10
A61P 17/00
A61P 11/00
A61P 25/28
A61K 48/00
A61P 13/12
C12N 5/02
A61P 3/10

US Classification:

4241351, 435375, 4241391, 4241331

Abstract:

The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.

US Patent:

20130326474, Dec 5, 2013

Filed:

May 13, 2009

Appl. No.:

12/465251

Inventors:

Thomas Lane - San Francisco CA, US

Assignee:

Adobe Systems Incorporated - San Jose CA

International Classification:

G06F 9/44

US Classification:

717107

Abstract:

A runtime environment can access code data defining an application comprising a persistent component comprising code for a user interface element and referencing a navigation action, a location loader, and a plurality of location components. Each location component can comprise executable code for child contents for providing a respective view of the application. A first view of the application can be provided by loading code of a first location component into memory via the location loader and executing code of the child contents of the first location component via the runtime environment. In response to receiving a navigation command via the user interface element, a second view of the application can be provided by loading code of a second location component into memory and executing code of the child contents of the second location component via the runtime environment. The code of the first location component may be removed from memory after the navigation command is received.